A Study Comparing IBI362 vs Semaglutide in Chinese Overweight or Obese Adults With Metabolic Dysfunction-associated Fatty Liver Disease （MAFLD）

NCT06884293 · clinicaltrials.gov ↗

PHASE3

Phase

ACTIVE_NOT_RECRUITING

Status

479

Enrollment

INDUSTRY

Sponsor class

Conditions

Overweight
Metabolic Dysfunction-associated Fatty Liver Disease (MAFLD)

Interventions

DRUG: IBI362
DRUG: semaglutide

Sponsor

Innovent Biologics (Suzhou) Co. Ltd.